Table 1.

Case Patient Hepatitis C Virus Treatment Regimen and Laboratory Characteristics

Year DAA Regimen Started	CD4 Count, Cells/μL, %	HIV VL, Copies/mL	IFNL3 Polymorphism	HCV Ab	APRI/FIB-4/ Child-Pugh Score	Pretreatment RAS	Pretreatment HCV VL (Genotype), IU/mL	DAA Regimen	On-treatment HCV VL	Duration, wk	Outcome
2015	532, 17	853		NEG	3.7/5.8/A	Unknown	7 017 000 (1b)	LDV/SOF	Not done (<15 not detected week 2 post-Rx)	12	Relapse
2016	n.d.	n.d.		n.d.	n.d.	Unknown	3 900 000 (not done)	ELV/GRZ + RBV	Week 2: <15 not detected	12	Relapse
2017	n.d.	<20 detected	CT	NEG	2.8/4.6/A	NS5A: L31M, Q54H, Y93H/Y; NS3: S122T	1 135 255 (1b)	SOF/VEL + RBV	Week 5: <15 not detected	24	Relapse
2018	391, 16	<20 not detected		NEG	1.4/3.2/A	NS5A: L31M, Y93H/Y; NS3: none; NS5B: not done	1 761 347 (1b)	SOF + GLE/PIB + RBV	Week 4: <15 detected	24	SVR 12

Abbreviations: APRI, AST-to-platelet ratio index; CD4, cluster of differentiation 4; DAA, direct-acting antiviral; ELV, elvitegravir; FIB-4, fibrosis-4; GLE, glecaprevir; HCV, hepatitis C virus; IFNL3, interferon lambda 3; LDV, ledipasvir; n.d., not done; NS3, nonstructural protein 3; NS5A, nonstructural protein 5A; NS5B, nonstructural protein 5B; glecaprevir; RAS, resistance-associated substitution; RBV, ribavirin; SOF, sofosbuvir; VEL, velpatasvir; VL, viral load.